| Dr Gary N Baskett, DO | |
|
2505 Mission Dr Ste 210, Wounds Center, Jefferson City, MO 65109-9508 | |
| (573) 681-3187 | |
| (573) 681-3645 |
| Full Name | Dr Gary N Baskett |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 39 Years |
| Location | 2505 Mission Dr Ste 210, Jefferson City, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922039817 | NPI | - | NPPES |
| 242238723 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 36749 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Missouri Home Health | Jefferson city, MO | Home health agency |
| Hospice Compassus-central Missouri | Jefferson city, MO | Hospice |
| Ssm Health St Mary's Hospital Jefferson City | Jefferson city, MO | Hospital |
| Miller County Care And Rehabilitation Center | Tuscumbia, MO | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ssm Regional Health Services | 8921917352 | 55 |
News Archive
The rapid growth in use of medical diagnostic imaging, such as CT scans, has led to widespread concern about radiation exposure in adults and the potential for future cancer risk in patients undergoing these tests.
UE LifeSciences Inc. (UELS), a medical device manufacturer focused on providing novel breast cancer screening solutions, announced today that it has received market clearance from the U.S. Food and Drug Administration (FDA) for its NoTouch BreastScan™ device. NoTouch BreastScan™ is a contactless breast-imaging tool cleared by the FDA specifically for adjunctive diagnostic screening for the detection of breast cancer.
Telik, Inc. today announced positive results from a Phase 2 multicenter trial of oral ezatiostat hydrochloride (TELINTRA, TLK199) in patients with an International Prognostic System Score of low to intermediate-1 risk myelodysplastic syndrome.
New research into the treatment, prognosis and early detection of gastrointestinal cancers was released today in advance of the ninth annual Gastrointestinal Cancers Symposium being held January 19-21, 2012, at The Moscone West Building in San Francisco, Calif.
› Verified 5 days ago
| Entity Name | Ssm Regional Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588601777 PECOS PAC ID: 8921917352 Enrollment ID: O20041105000902 |
News Archive
The rapid growth in use of medical diagnostic imaging, such as CT scans, has led to widespread concern about radiation exposure in adults and the potential for future cancer risk in patients undergoing these tests.
UE LifeSciences Inc. (UELS), a medical device manufacturer focused on providing novel breast cancer screening solutions, announced today that it has received market clearance from the U.S. Food and Drug Administration (FDA) for its NoTouch BreastScan™ device. NoTouch BreastScan™ is a contactless breast-imaging tool cleared by the FDA specifically for adjunctive diagnostic screening for the detection of breast cancer.
Telik, Inc. today announced positive results from a Phase 2 multicenter trial of oral ezatiostat hydrochloride (TELINTRA, TLK199) in patients with an International Prognostic System Score of low to intermediate-1 risk myelodysplastic syndrome.
New research into the treatment, prognosis and early detection of gastrointestinal cancers was released today in advance of the ninth annual Gastrointestinal Cancers Symposium being held January 19-21, 2012, at The Moscone West Building in San Francisco, Calif.
› Verified 5 days ago
| Entity Name | Ssm Regional Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043450711 PECOS PAC ID: 8921917352 Enrollment ID: O20050510000839 |
News Archive
The rapid growth in use of medical diagnostic imaging, such as CT scans, has led to widespread concern about radiation exposure in adults and the potential for future cancer risk in patients undergoing these tests.
UE LifeSciences Inc. (UELS), a medical device manufacturer focused on providing novel breast cancer screening solutions, announced today that it has received market clearance from the U.S. Food and Drug Administration (FDA) for its NoTouch BreastScan™ device. NoTouch BreastScan™ is a contactless breast-imaging tool cleared by the FDA specifically for adjunctive diagnostic screening for the detection of breast cancer.
Telik, Inc. today announced positive results from a Phase 2 multicenter trial of oral ezatiostat hydrochloride (TELINTRA, TLK199) in patients with an International Prognostic System Score of low to intermediate-1 risk myelodysplastic syndrome.
New research into the treatment, prognosis and early detection of gastrointestinal cancers was released today in advance of the ninth annual Gastrointestinal Cancers Symposium being held January 19-21, 2012, at The Moscone West Building in San Francisco, Calif.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gary N Baskett, DO 1020 Sassafrass Dr, Eldon, MO 65026-2151 Ph: (573) 746-0144 | Dr Gary N Baskett, DO 2505 Mission Dr Ste 210, Wounds Center, Jefferson City, MO 65109-9508 Ph: (573) 681-3187 |
News Archive
The rapid growth in use of medical diagnostic imaging, such as CT scans, has led to widespread concern about radiation exposure in adults and the potential for future cancer risk in patients undergoing these tests.
UE LifeSciences Inc. (UELS), a medical device manufacturer focused on providing novel breast cancer screening solutions, announced today that it has received market clearance from the U.S. Food and Drug Administration (FDA) for its NoTouch BreastScan™ device. NoTouch BreastScan™ is a contactless breast-imaging tool cleared by the FDA specifically for adjunctive diagnostic screening for the detection of breast cancer.
Telik, Inc. today announced positive results from a Phase 2 multicenter trial of oral ezatiostat hydrochloride (TELINTRA, TLK199) in patients with an International Prognostic System Score of low to intermediate-1 risk myelodysplastic syndrome.
New research into the treatment, prognosis and early detection of gastrointestinal cancers was released today in advance of the ninth annual Gastrointestinal Cancers Symposium being held January 19-21, 2012, at The Moscone West Building in San Francisco, Calif.
› Verified 5 days ago
Todd D Mccluskey, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3308 W Edgewood Dr, Suite B, Jefferson City, MO 65109 Phone: 573-893-7848 Fax: 573-893-1984 | |
Craig Alan Luetkemeyer, M.D. Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 1014 Madison St, Jefferson City, MO 65101 Phone: 573-644-6999 Fax: 573-644-7880 | |
Dr. Michael G. Steenbergen, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1241 W Stadium Blvd, Jefferson City, MO 65109 Phone: 573-635-5264 Fax: 573-634-7423 | |
Dr. James J. Weiss, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1241 W Stadium Blvd, Jefferson City, MO 65109 Phone: 573-635-5264 Fax: 573-634-7423 | |
Lorrie L Campbell, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1014 Madison St, Jefferson City, MO 65101 Phone: 573-644-6999 Fax: 573-644-7880 | |
Dr. Douglas N. Smith, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3308 W Edgewood Dr, Suite B, Jefferson City, MO 65109 Phone: 573-893-7848 Fax: 573-893-1984 | |
Michael Peter Dudenhoeffer, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 606 E High St, Jefferson City, MO 65101 Phone: 573-635-2211 Fax: 573-636-9350 |